Dr. Michael Ruscio, DC is a clinician, Naturopathic Practitioner, clinical researcher, author, and adjunct professor at the University of Bridgeport. His work has been published in peer-reviewed medical journals and he speaks at conferences around the globe.
Irritable bowel syndrome (IBS) is a common diagnosis given to people with chronic, otherwise unexplained abdominal pain, irregular bowel movements, and a host of other possible symptoms . Some people with IBS have diarrhea as a prominent feature and belong to an IBS subcategory called IBS-diarrhea, or IBS-D for short.
Needless to say, IBS-D can put a significant damper on your quality of life .
Although no cure currently exists for IBS-D, mounting evidence shows that lifestyle approaches may improve the condition and your quality of life. Such approaches may include eating a non-inflammatory diet, taking supplements to support digestion, reducing stress, correcting gut microbial imbalances, and making sure the bowels move regularly.
What Is IBS-D?
IBS-D is a subtype of IBS, which is a functional gastrointestinal disorder, or FGID . In FGIDs, the digestive tract stops doing its job properly, but not because of any structural issues or biochemical irregularities that can be detected in x-rays, blood tests, or microscopic views of the intestine . The Rome Foundation, which supplies doctors with a list of criteria to help them diagnose IBS, characterizes FGIDs as gut-brain axis disorders with the following :
Disturbed motility (muscular activity of the intestines)
Hypersensitive GI tract nerves
Abnormal functioning of the gut lining or immune system
Imbalances in gut microbiota
Impaired central nervous system communication
Estimates suggest that 10% to 12% of people in the United States have IBS, andfemales are three times as likely as males to have an IBS diagnosis .
About one-third of IBS sufferers have IBS-D, which means at least 25% of bowel movements appear as loose stools that are mushy without clear edges or completely liquid . Another third of IBS sufferers have IBS with constipation — IBS-C — indicated when 25% of bowel movements have hard or sausage-shaped stools that are lumpy. A final third of IBS patients have IBS-M, or mixed IBS, in which at least 25% of bowel movements reflect diarrhea or constipation .
Symptoms of IBS-D
Typically, IBS-D symptoms include sporadic abdominal pain or cramping and chronic diarrhea. IBS-D sufferers may also experience any of the following :
Abdominal bloating after meals or with stress
Feeling more full than makes sense
Dyspepsia or indigestion: burning sensations in the upper abdomen, often along with bloating, belching, and nausea
Mood disorders: emotions or moods that are inconsistent with the current situation and disrupt normal daily functioning and relationships
Chronic migraines: having headaches on at least 15 days per month with migraines on at least eight of those days for at least three months in a row
Interstitial cystitis: inflammation of the bladder that causes bladder or pelvic pressure and pain
Fibromyalgia: widespread muscle or joint pain, often with fatigue and disruptions in sleep, memory, and mood
Rarely, the sensation of incomplete or insufficient bowel movements; constipation may occur periodically in IBS-D
What Causes IBS-D?
Although the exact cause of IBS-D is unclear, research points to these possible underlying factors:
Dysbiosis or small intestinal bacterial overgrowth (SIBO): more than one-third of IBS patients may have SIBO [1, 5, 6, 7, 8, 9].
Gut infection: changes brought about by an immune attack on disease-causing microorganisms may disrupt intestinal motility even after the infection is cleared [1, 8].
Gut inflammation(gastroenteritis): a higher concentration of inflammatory cells, such as mast cells, cytokines, and eosinophils, may affect the nervous system and impair gut function [1, 10].
Food sensitivity: reactions to foods, such as FODMAPs , gluten , dairy products , and yeast  may irritate the gut lining, impairing motility and setting off immune reactions.
Malabsorption of bile acids: if bile acid from the gallbladder is not properly absorbed in the upper small intestine, it may flow into the large intestine and cause diarrhea-predominant IBS ; nearly 25% of IBS-D patients may have bile acid diarrhea of unknown cause .
People with IBS-D may be more likely to have a disorder called exocrine pancreatic insufficiency (EPI), in which the enzymes the pancreas produces to digest food are too few or otherwise unable to help with normal digestion. One study found that roughly 6% of people with IBS-D had EPI . At this point, the jury is out on whether EPI can be considered a cause of IBS or vice-versa, but it’s worth asking your doctor about it just to be sure.
How To Treat IBS-D
The optimal treatment plan for IBS-D consists of these steps:
Eat a healthier diet.
If IBS-D symptoms persist, eat a low-FODMAP diet.
Correct microbial imbalances.
Normalize (slow down) gut motility.
1. Eat a Healthier Diet
Frequently, just by making simple changes to the diet, people have seen significant improvements in their IBS-D symptoms . First-line dietary changes include reducing your intake of sugar, processed foods, alcohol, and caffeine, and increasing the amount of fruits and vegetables in your diet.
2. Eat a Low-FODMAP Diet
If the first-line dietary changes don’t seem to improve your IBS-D symptoms after a couple of weeks, the next thing to try is a low-FODMAP diet. The acronym FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols that occur in specific foods. These sugars and starches can feed gut dysbiosis, making high-FODMAP foods hard for IBS patients to digest and irritating to the gut lining. Clinical trials have found that a low-FODMAP diet improved GI symptoms and stool consistency and frequency, as well as the quality of life, anxiety, and work productivity, in people with IBS-D [18, 19, 20].
3. Support Digestion
If you’re still not seeing improvements to your IBS-D symptoms, certain supplements may give your gut the boost it needs. Probiotics, immunoglobulins, and digestive enzymes may give your digestive system a hand at breaking down food and absorbing nutrients.
Probiotics: Although some conflicting studies exist , probiotics in clinical trials have largely improved IBS-D symptoms, including diarrhea [22, 23, 24, 25, 26].
If EPI appears to be an issue, pancreatic enzyme replacement therapy (called PERT for short), a doctor-prescribed treatment for EPI, may be helpful .
4. Reduce Stress
Stress is a pretty regular part of most people’s lives and a likely contributor to your IBS-D symptoms. Several types of evidence-based practices have shown positive effects at reducing stress and specifically improving life for IBS patients.
Moderate exercise can reduce stress and may have important benefits to IBS patients .
Psychological support. In people with moderate to severe IBS-D, working with therapists who offered cognitive-behavioral therapy (CBT) or mindfulness-based stress reduction (MBSR), helped improve their quality of life .
Hypnotherapy. Gut-focused hypnotherapy may help reduce IBS symptoms and improve quality of life , even when done via online video .
5. Correct Microbial Imbalances
If the previous approaches don’t seem to help, SIBO or other types of dysbiosis may be part of the picture. Probiotic therapy is my first choice for treating dysbiosis, but for those who don’t respond to probiotics, herbal antimicrobials or prescription antibiotics may be warranted.
Probiotics. Although many believe that probiotics should not be used in cases of SIBO or dysbiosis, research clearly refutes this idea . Clinical trials have shown probiotics to reduce SIBO [31, 32, 33] and other infections, such as H. pylori , parasites , and fungi [36, 37].
Herbal antimicrobials. Although fewer studies exist for herbal antimicrobial treatments for IBS and SIBO, herbal preparations may be as effective as prescription antibiotics at treating both [38, 39]. Berberine, in particular, has reduced the frequency of diarrhea, abdominal pain, and urgency, as well as improved quality of life in IBS-D patients [38, 40].
Rifaximin. With the brand name Xifaxan, this FDA-approved intestine-specific antibiotic may help modulate gut microbiota, inflammation, hypersensitivity, and intestinal permeability [41, 42].
6. Normalize (Slow Down) Gut Motility
Diarrhea happens when gut motility is too fast. Diarrhea causes dehydration and malabsorption, both of which can become serious issues if diarrhea becomes chronic. If IBS-related diarrhea persists after consistently applying dietary changes, digestive supports, stress reduction practices, and microbial balancing, the following conventional medications may be helpful.
Loperamide. Brand name Imodium, this over-the-counter anti-diarrheal may help slow motility temporarily, but few clinical trials have researched its use in IBS .
Eluxadoline. With the brand name Viberzi, this FDA-approved prescription drug targets opioid receptors in the digestive tract to slow motility, reduce water entering the intestine, and decrease pain perception [41, 42].
Alosetron. With the brand name Lotronex, this FDA-approved prescription drug modulates nerve signals and slows motility [41, 42].
Peppermint oil is an herbal supplement that may relax the smooth muscles in the digestive tract, helping to decrease pain, bloating, and bowel movement urgency. But it commonly produces side effects, including heartburn or indigestion , so test it carefully.
If your doctor finds your stool has high levels of steatocrit, bile acid malabsorption (BAM) is likely causing your chronic diarrhea. Conventional medications that can help address this include bile acid binders , such as:
Important Notes About Medication:
The FDA considers drugs as a bottom-of-the-list option for IBS, to be considered only if lifestyle changes don’t help .
Dicyclomine: With the brand name Bentyl, this is another prescription drug that has been used to treat pain in IBS-D, but the FDA does not recommend using it because of side effects, including fatigue, dizziness, dry eyes, and dry mouth .
How Is IBS-D Diagnosed?
I recommend working with a gut specialist to find out whether you have IBS-D. As is true for all IBS subtypes, doctors have no clear path to diagnosing IBS-D. Without specific blood tests or other diagnostic panels to indicate IBS-D, primary care doctors and gastroenterologists typically have to first rule out conditions caused by structural or biochemical problems, including :
Inflammatory bowel disease (IBD)
Chronic GI infections
Primary bile acid diarrhea
If general blood tests, various breath tests, or colonoscopies don’t indicate these conditions, doctors may then use a set of questions, called the Rome IV criteria, combined with your health and family histories to decide whether you likely suffer from IBS-D .
Final Thoughts on IBS-D
IBS-D is simply a subtype of IBS that has diarrhea as a prominent symptom. It’s possible to switch back and forth between IBS-D and IBS-C, putting you in the mixed-type — or IBS-M — a category of people who suffer from IBS. In any case, the label is not as important as your symptoms and how they affect your life.
The good news is that when the right supports are in place, people can and do shift to a symptom-free existence and a higher quality of life. Until then, when IBS-D is part of your day-to-day life, this article can be your guide to finding appropriate care and giving your body the special support it needs.
Kurin M, Cooper G. Irritable bowel syndrome with diarrhea: Treatment is a work in progress. Cleve Clin J Med. 2020 Jul 31;87(8):501-511. doi: 10.3949/ccjm.87a.19011. PMID: 32737051.
Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020 May/Jun;43(3):E102-E122. doi: 10.1097/SGA.0000000000000530. PMID: 32487960.
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018 Jul;53(7):807-818. doi: 10.1007/s00535-018-1476-9. Epub 2018 May 14. PMID: 29761234.
Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Rev Gastroenterol Mex. 2014 Apr-Jun;79(2):96-134. English, Spanish. doi: 10.1016/j.rgmx.2014.01.004. Epub 2014 May 23. PMID: 24857420.
Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. Front Psychiatry. 2020 Jul 10;11:664. doi: 10.3389/fpsyt.2020.00664. PMID: 32754068; PMCID: PMC7366247.
Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002 Dec;47(12):2639-43. doi: 10.1023/a:1021039032413. PMID: 12498278.
Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017 Apr;49(4):331-337. doi: 10.1016/j.dld.2017.01.142. Epub 2017 Jan 21. PMID: 28179092.
Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterol. 2009 Aug 7;15(29):3591-6. doi: 10.3748/wjg.15.3591. PMID: 19653335; PMCID: PMC2721231.
Catassi C, Alaedini A, Bojarski C, Bonaz B, Bouma G, Carroccio A, Castillejo G, De Magistris L, Dieterich W, Di Liberto D, Elli L, Fasano A, Hadjivassiliou M, Kurien M, Lionetti E, Mulder CJ, Rostami K, Sapone A, Scherf K, Schuppan D, Trott N, Volta U, Zevallos V, Zopf Y, Sanders DS. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients. 2017 Nov 21;9(11):1268. doi: 10.3390/nu9111268. PMID: 29160841; PMCID: PMC5707740.
Deng Y, Misselwitz B, Dai N, Fox M. Lactose Intolerance in Adults: Biological Mechanism and Dietary Management. Nutrients. 2015 Sep 18;7(9):8020-35. doi: 10.3390/nu7095380. PMID: 26393648; PMCID: PMC4586575.
Atkinson W, Sheldon TA, Shaath N, et al
Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial
Aziz I, Mumtaz S, Bholah H, Chowdhury FU, Sanders DS, Ford AC. High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1650-5.e2. doi: 10.1016/j.cgh.2015.03.002. Epub 2015 Mar 10. PMID: 25769413.
Leeds JS, Hopper AD, Sidhu R, Simmonette A, Azadbakht N, Hoggard N, Morley S, Sanders DS. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010 May;8(5):433-8. doi: 10.1016/j.cgh.2009.09.032. Epub 2009 Oct 14. PMID: 19835990.
McKenzie, Y.A., Bowyer, R.K., Leach, H., Gulia, P., Horobin, J., O’Sullivan, N.A., Pettitt, C., Reeves, L.B., Seamark, L., Williams, M., Thompson, J. & Lomer, M.C.E. (2016) British Dietetic Association systematic review and evidence‐based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 29, 549– 575 doi:10.1111/jhn.12385
Zahedi MJ, Behrouz V, Azimi M. Low fermentable oligo-di-mono-saccharides and polyols diet versus general dietary advice in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled trial. J Gastroenterol Hepatol. 2018 Jun;33(6):1192-1199. doi: 10.1111/jgh.14051. Epub 2018 Feb 21. PMID: 29159993.
Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016 Dec;111(12):1824-1832. doi: 10.1038/ajg.2016.434. Epub 2016 Oct 11. PMID: 27725652.
Eswaran S, Chey WD, Jackson K, Pillai S, Chey SW, Han-Markey T. A Diet Low in Fermentable Oligo-, Di-, and Monosaccharides and Polyols Improves Quality of Life and Reduces Activity Impairment in Patients With Irritable Bowel Syndrome and Diarrhea. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1890-1899.e3. doi: 10.1016/j.cgh.2017.06.044. Epub 2017 Jun 28. PMID: 28668539.
Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil. 2017 Jul;29(7). doi: 10.1111/nmo.13037. Epub 2017 Mar 8. PMID: 28271623.
Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2018 May 25;18(1):71. doi: 10.1186/s12876-018-0788-9. PMID: 29801486; PMCID: PMC5970461.
Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2018 Feb 14;8(1):2964. doi: 10.1038/s41598-018-21241-z. PMID: 29445178; PMCID: PMC5813237.
Preston K, Krumian R, Hattner J, de Montigny D, Stewart M, Gaddam S. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes. 2018 Sep 18;9(5):697-706. doi: 10.3920/BM2017.0105. Epub 2018 Jun 11. PMID: 29888656.
Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench. 2014 Summer;7(3):156-63. PMID: 25120896; PMCID: PMC4129566.
Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016 Feb 27;15:21. doi: 10.1186/s12937-016-0140-6. PMID: 26922379; PMCID: PMC4769834.
Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2013 Dec 5;6:49-60. doi: 10.4137/CGast.S13200. PMID: 24833942; PMCID: PMC4020402.
Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: A systematic review of randomized controlled trials. Neurogastroenterol Motil. 2019 Feb;31(2):e13461. doi: 10.1111/nmo.13461. Epub 2018 Sep 19. PMID: 30232834.
Miller V, Carruthers HR, Morris J, Hasan SS, Archbold S, Whorwell PJ. Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther. 2015 May;41(9):844-55. doi: 10.1111/apt.13145. Epub 2015 Mar 4. PMID: 25736234.
Hasan SS, Pearson JS, Morris J, Whorwell PJ. SKYPE HYPNOTHERAPY FOR IRRITABLE BOWEL SYNDROME: Effectiveness and Comparison with Face-to-Face Treatment. Int J Clin Exp Hypn. 2019 Jan-Mar;67(1):69-80. doi: 10.1080/00207144.2019.1553766. PMID: 30702396; PMCID: PMC6538308.
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017 Apr;51(4):300-311. doi: 10.1097/MCG.0000000000000814. PMID: 28267052.
García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, Montes-Cortes DH, Medina G, Cruz-Domínguez MP. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020 Apr;65(4):1134-1143. doi: 10.1007/s10620-019-05830-0. Epub 2019 Sep 23. PMID: 31549334.
Greco A, Caviglia GP, Brignolo P, Ribaldone DG, Reggiani S, Sguazzini C, Smedile A, Pellicano R, Resegotti A, Astegiano M, Bresso F. Glucose breath test and Crohn’s disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015;50(11):1376-81. doi: 10.3109/00365521.2015.1050691. Epub 2015 May 19. PMID: 25990116.
Wang F, Feng J, Chen P, Liu X, Ma M, Zhou R, Chang Y, Liu J, Li J, Zhao Q. Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):466-475. doi: 10.1016/j.clinre.2017.04.004. Epub 2017 May 25. PMID: 28552432.
Besirbellioglu BA, Ulcay A, Can M, Erdem H, Tanyuksel M, Avci IY, Araz E, Pahsa A. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis. 2006;38(6-7):479-81. doi: 10.1080/00365540600561769. PMID: 16798698.
Demirel G, Celik IH, Erdeve O, Saygan S, Dilmen U, Canpolat FE. Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. Eur J Pediatr. 2013 Oct;172(10):1321-6. doi: 10.1007/s00431-013-2041-4. Epub 2013 May 24. PMID: 23703468.
Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res. 2011 Mar;108(3):541-5. doi: 10.1007/s00436-010-2095-4. Epub 2010 Oct 5. PMID: 20922415.
Chen C, Tao C, Liu Z, Lu M, Pan Q, Zheng L, Li Q, Song Z, Fichna J. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Phytother Res. 2015 Nov;29(11):1822-7. doi: 10.1002/ptr.5475. Epub 2015 Sep 24. PMID: 26400188.
Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E, Mullin GE. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014 May;3(3):16-24. doi: 10.7453/gahmj.2014.019. PMID: 24891990; PMCID: PMC4030608.
Di Pierro F, Bertuccioli A, Giuberti R, Saponara M, Ivaldi L. Role of a berberine-based nutritional supplement in reducing diarrhea in subjects with functional gastrointestinal disorders. Minerva Gastroenterol Dietol. 2020 Mar;66(1):29-34. doi: 10.23736/S1121-421X.19.02649-7. PMID: 32283882.
Brenner DM, Sayuk GS. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther. 2020 Jan;37(1):83-96. doi: 10.1007/s12325-019-01116-z. Epub 2019 Nov 9. PMID: 31707713.
Munjal A, Dedania B, Cash BD. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2020 Jan;21(1):63-71. doi: 10.1080/14656566.2019.1691524. Epub 2019 Nov 18. PMID: 31738621.
Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol. 2020 Nov 12:S2468-1253(20)30212-0. doi: 10.1016/S2468-1253(20)30212-0. Epub ahead of print. PMID: 33189181.
Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017 Oct 26;6(11):99. doi: 10.3390/jcm6110099. PMID: 29072609; PMCID: PMC5704116.
Need help or would like to learn more?
View Dr. Ruscio’s, DC additional resources
I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!
Transform your health
Every product is science-based, validated by real-world use, and personally vetted by Dr. Ruscio, DC.